Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Krouwels, P. de Haan, M. Dahele, B. Hajian, I. van der Lee (Hoofddorp, Amsterdam, Netherlands). Concurrent chemoradiation in stage III NSCLC: High eligilbility and high rates of overall and progression-free survival with acceptable toxicity. Eur Respir J 2013; 42: Suppl. 57, 2886

Member's Comments

No comment yet.

Related content which might interest you: The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Impact of early weight loss during concurrent chemoradiotherapy on survival in advanced stage NSCLC patients Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Treatment of unresectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Attempting tissue diagnosis in performance status 3 and 4 lung cancer patients may not influence treatment or survival Source: Annual Congress 2013 –Quality management in thoracic oncology Year: 2013 Long-term survival is linked to serum LDH normalization in SCLC Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013